Intravenous immunoglobulin: a safe option for treatment of steroid-resistant rejection in the presence of infection.
Management of recurrent allograft rejection is a risky proposition, especially in the presence of infections. Both steroids and antibody therapy worsen the infection risk. We successfully treated steroid-resistant rejection with intravenous immunoglobulin (IVIG) in two patients who had concomitant infections. IVIG should be considered the treatment of choice for management of steroid-resistant rejection in the presence of serious infection.
Moger
Venkatesh
V
Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Ravishankar
Machiraju S
MS
Sakhuja
Vinay
V
Kohli
Harbir S
HS
Sud
Kamal
K
Gupta
Krishan L
KL
Jha
Vivekanand
V
D000328:Adult; D003586:Cytomegalovirus Infections / Q000150:complications*; D004351:Drug Resistance; D004927:Escherichia coli Infections / Q000150:complications*; D006084:Graft Rejection / Q000150:complications / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous; D016030:Kidney Transplantation; D008297:Male; D013256:Steroids / Q000627:therapeutic use
D016756:Immunoglobulins, Intravenous; D013256:Steroids